Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29221381 | 1.00 | MDM4 (0.49) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL30927131 | 1.00 | MDM4 (0.49) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL29221384 | 1.00 | MDM4 (0.49) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL19437212 | 0.96 | MDM4 (0.49) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL19437214 | 0.96 | MDM4 (0.49) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL26509390 | 0.93 | MDM2 (0.46) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL1514663 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL29400401 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL799706 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL3736523 | 0.89 | MDM4 (0.52) | MDM4TP53MDM2PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4441069-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4373835-A1 | MACROCYLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4370530-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023102507-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023288213-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 3040/4885TP53 421/4885MDM2 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.